Clinical Drug Investigation

, Volume 13, Issue 1, pp 15–22 | Cite as

CR FIRST

An Interim Report of a 5-Year Clinical Study in Patients with Parkinson’s Disease with No Prior Levodopa Therapy
  • C. Liss
  • D. Bush
  • B. Last
  • B. Smith
  • G. Block
  • S. Reines
Clinical Use

Summary

CR FIRST (Sinemet® CR Five Year International Response Fluctuation Study) is a multicentre clinical trial (currently in its fifth year of implementation) designed to test the hypothesis that long term treatment of patients with Parkinson’s disease with a controlled-release formulation of levodopa (Sinemet® CR) will extend the time until the onset of clinical response fluctuations. CR FIRST was designed with sufficient power to detect a clinically significant treatment effect, if one exists. A total of 618 levodopa-natïve patients with Parkinson’s disease, who required therapy with levodopa, were enrolled at 36 sites throughout the world. Patients were randomised to receive 1 tablet twice a day of either immediate-release Sinemet® 25/100 (carbidopa/levodopa) or Sinemet® CR 50/200, then titrated according to response. Patients are being evaluated at regular intervals over 5 years to determine if and when the primary end-point of response fluctuations is attained. At baseline, the cohort represented a moderately disabled patient population, as evidenced by an average Hoehn and Yahr state of 1.9 and an average duration since diagnosis of 2.3 years. As expected, the CR FIRST population had a higher degree of disease severity than patients in the Deprenyl and Tochopherol Antioxidative Therapy of Parkinsonism (DATATOP) cohort. The 2 populations were very similar with regard to demographic characteristics.

Keywords

Levodopa Adis International Limited Drug Invest Selegiline Motor Fluctuation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol 1989; 46: 1052–60CrossRefGoogle Scholar
  2. 2.
    Barbeau A. The clinical physiology of side effects in long term L-dopa therapy. Adv Neurol 1974; 5: 347–65PubMedGoogle Scholar
  3. 3.
    Marsden CD, Parkes JD. ‘On-off’ effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1976; II: 292–6CrossRefGoogle Scholar
  4. 4.
    Sweet RD, McDowell FH. Plasma dopa concentrations and the ‘on-off’ effect after chronic treatment of Parkinson’s disease. Neurology 1974; 24: 953–6PubMedCrossRefGoogle Scholar
  5. 5.
    Quinn NP, Levodopa. In: Koller WC, editor. Handbook of Parkinson’s disease. New York: Marcel Dekker; 1987: 317–37Google Scholar
  6. 6.
    Chase TN, Baronti F, Fabbrini GI, et al. Rationale for continuous dopaminomimetic therapy of Parkinson’s disease. Neurology 1989; 39(2): 7–10PubMedGoogle Scholar
  7. 7.
    Olanow CW. Oxidation reactions in Parkinson’s disease. Neurology 1990; 40: 32–7PubMedGoogle Scholar
  8. 8.
    Blin J, Bonnett AM, Agid Y. Does levodopa aggravate Parkinson’s disease? Neurology 1988; 38(9): 1410–6PubMedCrossRefGoogle Scholar
  9. 9.
    Quinn NP, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous infusion of levodopa. Neurology 1984; 34: 1131–6PubMedCrossRefGoogle Scholar
  10. 10.
    Juncos J, Serrati C, Fabbrini G, et al. Fluctuating levodopa concentrations in Parkinson’s disease. Lancet 1985; II: 440CrossRefGoogle Scholar
  11. 11.
    Cedarbaum JM. The promise and limitations of controlled release oral levodopa administration. Clin Neuropharmacol 1989; 12: 147–66PubMedCrossRefGoogle Scholar
  12. 12.
    Marsden CD. Parkinson’s disease. Lancet 1990; 335: 948–52PubMedCrossRefGoogle Scholar
  13. 13.
    Duvoisin RC. New strategies in dopaminergic therapy of Parkinson’s disease: the use of a controlled-release formulation. Neurology 1989; 39(2): 4–6PubMedGoogle Scholar
  14. 14.
    Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321(20): 1364–71CrossRefGoogle Scholar
  15. 15.
    Gauthier S, Amyot D. Sustained release antiparkinson agents: controlled release levodopa. Can J Neurol Sci 1992; 19: 153–5PubMedGoogle Scholar
  16. 16.
    Alba A, Trainor FS, Ritter W, et al. A clinical disability rating for Parkinson’s patients. J Chron Dis 1968; 21: 507–22PubMedCrossRefGoogle Scholar
  17. 17.
    Canter CJ, de la Torre R, Mier M. A method of evaluating disability in patients with Parkinson’s disease. J Nerv Ment Dis 1961; 133: 143–7PubMedCrossRefGoogle Scholar
  18. 18.
    Fahn S, Elton RL, members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, et al, editors. Recent developments in Parkinson’s disease II. Florham Park, NJ: Macmillan, 1987Google Scholar
  19. 19.
    Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–42PubMedCrossRefGoogle Scholar
  20. 20.
    Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson IML, editors. Third symposium on Parkinson’s disease. Edinburgh, UK: Livingstone, 1969: 152–7Google Scholar
  21. 21.
    Hunt SM, McEwen J, McKenna SP. Measuring health status. Dover, NH; Croom Helm, 1986Google Scholar
  22. 22.
    Elandt-Johnson C, Johnson NL. Survival models and data analysis. New York; John Wiley, 1980Google Scholar
  23. 23.
    Lachin JM, Foulkes MA, Evaluation of sample size and power for analysis of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986; 42: 507–19PubMedCrossRefGoogle Scholar
  24. 24.
    Schoenberg BS. Descriptive epidemiology of Parkinson’s disease: disease distribution and hypothesis formulation. Adv Neurol 1986; 45: 277–83Google Scholar
  25. 25.
    Hoehn MM. Parkinson’s disease: progression and mortality. Adv Neurol 1986; 45: 457–61Google Scholar
  26. 26.
    DuPont E, Anderson A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996; 93: 14–20PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • C. Liss
    • 1
  • D. Bush
    • 2
  • B. Last
    • 1
  • B. Smith
    • 1
  • G. Block
    • 1
  • S. Reines
    • 1
  1. 1.Merck Research Laboratories, BL 3-2West PointUSA
  2. 2.Pacific Quintiles, Inc.San DiegoUSA

Personalised recommendations